Pink1-deficiency in mice impairs gait, olfaction and serotonergic innervation of the olfactory bulb

Experimental Neurology

Volumn 235, Issue 1, 2012, Pages 214-227

  Glasl, Lisa ^a   Kloos, Karina ^a   Giesert, Florian ^a   Roethig, Anne ^a   Di Benedetto, Barbara ^b   Kühn, Ralf ^a   Zhang, Jingzhong ^a   Hafen, Ulrich ^a   Zerle, Julia ^a   Hofmann, Andreas ^a   Hrabé de Angelis, Martin ^a   Winklhofer, Konstanze F ^c,d   Hölter, Sabine M ^a   Vogt Weisenhorn, Daniela M ^a   Wurst, Wolfgang ^a,c,d  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Compensation; Early onset Parkinson's Disease; Gait impairment; Genetic mouse model; Mitochondrial dysfunction; Olfactory dysfunction

Indexed keywords

GENOMIC DNA; MESSENGER RNA; PROTEIN KINASE; PTEN INDUCED KINASE 1; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; BRADYKINESIA; CELL DENSITY; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; ENZYME DEFICIENCY; GAIT DISORDER; GENE; GENE EXPRESSION; GENE SILENCING; LOSS OF FUNCTION MUTATION; MITOCHONDRION; MOTOR DYSFUNCTION; MOUSE; MUSCLE RIGIDITY; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; OLFACTORY BULB; OLFACTORY DISCRIMINATION; PARKINSON DISEASE; PINK1 GENE; PRIORITY JOURNAL; RELIABILITY; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; SMELLING DISORDER; SYMPTOM; TREMOR;

ADRENERGIC NEURONS; ANIMALS; CELL COUNT; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; GAIT; MICE; MITOCHONDRIA; MOTOR ACTIVITY; OLFACTORY BULB; PROTEIN KINASES; SEROTONERGIC NEURONS; SMELL;

EID: 84862777779     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.01.002     Document Type: Article

References (80)

1. Abou-Sleiman P.M., Muqit M.M., Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 2006, 7:207-219.
2. Alam M., Schwabe K., Krauss J.K. The pedunculopontine nucleus area: critical evaluation of interspecies differences relevant for its use as a target for deep brain stimulation. Brain 2011, 134:11-23.
3. Andres-Mateos E., Perier C., Zhang L., Blanchard-Fillion B., Greco T.M., Thomas B., Ko H.S., Sasaki M., Ischiropoulos H., Przedborski S., Dawson T.M., Dawson V.L. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14807-14812.
4. Baltadjieva R., Giladi N., Gruendlinger L., Peretz C., Hausdorff J.M. Marked alterations in the gait timing and rhythmicity of patients with de novo Parkinson's disease. Eur. J. Neurosci. 2006, 24:1815-1820.
5. Berendse H.W., Booij J., Francot C.M., Bergmans P.L., Hijman R., Stoof J.C., Wolters E.C. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann. Neurol. 2001, 50:34-41.
6. Blackinton J.G., Anvret A., Beilina A., Olson L., Cookson M.R., Galter D. Expression of PINK1 mRNA in human and rodent brain and in Parkinson's disease. Brain Res 2007, 1184:10-16.
7. Braak H., Ghebremedhin E., Rub U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004, 318:121-134.
8. Chen L., Cagniard B., Mathews T., Jones S., Koh H.C., Ding Y., Carvey P.M., Ling Z., Kang U.J., Zhuang X. Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J. Biol. Chem. 2005, 280:21418-21426.
9. Collier T.J., Kanaan N.M., Kordower J.H. Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat. Rev. Neurosci. 2011, 12:359-366.
10. Da Prada M., Cesura A.M., Launay J.M., Richards J.G. Platelets as a model for neurones?. Experientia 1988, 44:115-126.
11. Dagda R.K., Cherra S.J., Kulich S.M., Tandon A., Park D., Chu C.T. Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J. Biol. Chem. 2009, 284:13843-13855.
12. Dagerlind A., Friberg K., Bean A.J., Hokfelt T. Sensitive mRNA detection using unfixed tissue: combined radioactive and non-radioactive in situ hybridization histochemistry. Histochemistry 1992, 98:39-49.
13. Deng H., Dodson M.W., Huang H., Guo M. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14503-14508.
14. Devos D., Defebvre L., Bordet R. Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson's disease. Fundam. Clin. Pharmacol. 2010, 24:407-421.
15. Di Matteo V., Pierucci M., Esposito E., Crescimanno G., Benigno A., Di Giovanni G. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders. Prog. Brain Res. 2008, 172:423-463.
16. Doty R.L., Riklan M., Deems D.A., Reynolds C., Stellar S. The olfactory and cognitive deficits of Parkinson's disease: evidence for independence. Ann. Neurol. 1989, 25:166-171.
17. Doty R.L., Stern M.B., Pfeiffer C., Gollomp S.M., Hurtig H.I. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1992, 55:138-142.
18. Enwere E., Shingo T., Gregg C., Fujikawa H., Ohta S., Weiss S. Aging results in reduced epidermal growth factor receptor signaling, diminished olfactory neurogenesis, and deficits in fine olfactory discrimination. J Neurosci. 2004, 24:8354-8365.
19. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann. N.Y. Acad. Sci. 2003, 991:1-14.
20. Feil R., Hölter S.M., Weindl K., Wurst W., Langmesser S., Gerling A., Feil S., Albrecht U. cGMP-dependent protein kinase I, the circadian clock, sleep and learning. Commun. Integr. Biol. 2009, 2:298-301.
21. Ferraris A., Ialongo T., Passali G.C., Pellecchia M.T., Brusa L., Laruffa M., Guidubaldi A., Paludetti G., Albanese A., Barone P., Dallapiccola B., Valente E.M., Bentivoglio A.R. Olfactory dysfunction in Parkinsonism caused by PINK1 mutations. Mov. Disord. 2009, 24:2350-2357.
22. Ferrer I. Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease. Park. Dis. 2011, 2011:708404.
23. Fox S.H., Chuang R., Brotchie J.M. Serotonin and Parkinson's disease: on movement, mood, and madness. Mov. Disord. 2009, 24:1255-1266.
24. Gandhi S., Muqit M.M., Stanyer L., Healy D.G., Abou-Sleiman P.M., Hargreaves I., Heales S., Ganguly M., Parsons L., Lees A.J., Latchman D.S., Holton J.L., Wood N.W., Revesz T. PINK1 protein in normal human brain and Parkinson's disease. Brain 2006, 129:1720-1731.
25. Gautier C.A., Kitada T., Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:11364-11369.
26. Geisler S., Holmstrom K.M., Skujat D., Fiesel F.C., Rothfuss O.C., Kahle P.J., Springer W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 2010, 12:119-131.
27. Geula C., Mesulam M.M. Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cereb. Cortex 1996, 6:165-177.
28. Gispert S., Ricciardi F., Kurz A., Azizov M., Hoepken H.H., Becker D., Voos W., Leuner K., Muller W.E., Kudin A.P., Kunz W.S., Zimmermann A., Roeper J., Wenzel D., Jendrach M., Garcia-Arencibia M., Fernandez-Ruiz J., Huber L., Rohrer H., Barrera M., Reichert A.S., Rub U., Chen A., Nussbaum R.L., Auburger G. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One 2009, 4:e5777.
29. Goldberg M.S., Pisani A., Haburcak M., Vortherms T.A., Kitada T., Costa C., Tong Y., Martella G., Tscherter A., Martins A., Bernardi G., Roth B.L., Pothos E.N., Calabresi P., Shen J. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 2005, 45:489-496.
30. Haehner A., Hummel T., Hummel C., Sommer U., Junghanns S., Reichmann H. Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov. Disord. 2007, 22:839-842.
31. Hamers F.P., Lankhorst A.J., van Laar T.J., Veldhuis W.B., Gispen W.H. Automated quantitative gait analysis during overground locomotion in the rat: its application to spinal cord contusion and transection injuries. J. Neurotrauma 2001, 18:187-201.
32. Harding A.J., Stimson E., Henderson J.M., Halliday G.M. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 2002, 125:2431-2445.
33. Hendricks T., Francis N., Fyodorov D., Deneris E.S. The ETS domain factor Pet-1 is an early and precise marker of central serotonin neurons and interacts with a conserved element in serotonergic genes. J Neurosci. 1999, 19:10348-10356.
34. Huisman E., Uylings H.B., Hoogland P.V. Gender-related changes in increase of dopaminergic neurons in the olfactory bulb of Parkinson's disease patients. Mov. Disord. 2008, 23:1407-1413.
35. Itier J.M., Ibanez P., Mena M.A., Abbas N., Cohen-Salmon C., Bohme G.A., Laville M., Pratt J., Corti O., Pradier L., Ret G., Joubert C., Periquet M., Araujo F., Negroni J., Casarejos M.J., Canals S., Solano R., Serrano A., Gallego E., Sanchez M., Denefle P., Benavides J., Tremp G., Rooney T.A., Brice A., Garcia de Yebenes J. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Gen. 2003, 12:2277-2291.
36. Jacobs B.L., Fornal C.A. 5-HT and motor control: a hypothesis. Trends Neurosci. 1993, 16:346-352.
37. Kawajiri S., Saiki S., Sato S., Hattori N. Genetic mutations and functions of PINK1. Trends Pharmacol. Sci. 2011, 32:573-580.
38. Kim R.H., Smith P.D., Aleyasin H., Hayley S., Mount M.P., Pownall S., Wakeham A., You-Ten A.J., Kalia S.K., Horne P., Westaway D., Lozano A.M., Anisman H., Park D.S., Mak T.W. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5215-5220.
39. Kitada T., Pisani A., Porter D.R., Yamaguchi H., Tscherter A., Martella G., Bonsi P., Zhang C., Pothos E.N., Shen J. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11441-11446.
40. Kumazawa R., Tomiyama H., Li Y., Imamichi Y., Funayama M., Yoshino H., Yokochi F., Fukusako T., Takehisa Y., Kashihara K., Kondo T., Elibol B., Bostantjopoulou S., Toda T., Takahashi H., Yoshii F., Mizuno Y., Hattori N. Mutation analysis of the PINK1 gene in 391 patients with Parkinson disease. Arch. Neurol. 2008, 65:802-808.
41. Liu W., Acin-Perez R., Geghman K.D., Manfredi G., Lu B., Li C. Pink1 regulates the oxidative phosphorylation machinery via mitochondrial fission. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:12920-12924.
42. Lutz A.K., Exner N., Fett M.E., Schlehe J.S., Kloos K., Lammermann K., Brunner B., Kurz-Drexler A., Vogel F., Reichert A.S., Bouman L., Vogt-Weisenhorn D., Wurst W., Tatzelt J., Haass C., Winklhofer K.F. Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation. J. Biol. Chem. 2009, 284:22938-22951.
43. Marongiu R., Ferraris A., Ialongo T., Michiorri S., Soleti F., Ferrari F., Elia A.E., Ghezzi D., Albanese A., Altavista M.C., Antonini A., Barone P., Brusa L., Cortelli P., Martinelli P., Pellecchia M.T., Pezzoli G., Scaglione C., Stanzione P., Tinazzi M., Zecchinelli A., Zeviani M., Cassetta E., Garavaglia B., Dallapiccola B., Bentivoglio A.R., Valente E.M. PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. Hum. Mutat. 2008, 29:565.
44. Metz G.A., Tse A., Ballermann M., Smith L.K., Fouad K. The unilateral 6-OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis. Eur. J. Neurosci. 2005, 22:735-744.
45. Mihalick S.M., Langlois J.C., Krienke J.D., Dube W.V. An olfactory discrimination procedure for mice. J. Exp. Anal. Behav. 2000, 73:305-318.
46. Mirelman A., Gurevich T., Giladi N., Bar-Shira A., Orr-Urtreger A., Hausdorff J.M. Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann. Neurol. 2011, 69:193-197.
47. Monaghan M.M., Leddy L., Sung M.L., Albinson K., Kubek K., Pangalos M.N., Reinhart P.H., Zaleska M.M., Comery T.A. Social odor recognition: a novel behavioral model for cognitive dysfunction in Parkinson's disease. Neurodegenerative Dis. 2010, 7:153-159.
48. Morais V.A., Verstreken P., Roethig A., Smet J., Snellinx A., Vanbrabant M., Haddad D., Frezza C., Mandemakers W., Vogt-Weisenhorn D., Van Coster R., Wurst W., Scorrano L., De Strooper B. Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function. EMBO Mol. Med. 2009, 1:99-111.
49. Morris M.E., Huxham F., McGinley J., Dodd K., Iansek R. The biomechanics and motor control of gait in Parkinson disease. Clin. Biomech. 2001, 16:459-470.
50. Narendra D.P., Youle R.J. Targeting mitochondrial dysfunction: role for PINK1 and Parkin in mitochondrial quality control. Antioxid. Redox Signal. 2011, 14:1929-1938.
51. Narendra D.P., Jin S.M., Tanaka A., Suen D.F., Gautier C.A., Shen J., Cookson M.R., Youle R.J. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 2010, 8:e1000298.
52. Pearce R.K., Hawkes C.H., Daniel S.E. The anterior olfactory nucleus in Parkinson's disease. Mov. Disord. 1995, 10:283-287.
53. Perez F.A., Palmiter R.D. Parkin-deficient mice are not a robust model of parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:2174-2179.
54. Petzold G.C., Hagiwara A., Murthy V.N. Serotonergic modulation of odor input to the mammalian olfactory bulb. Nat. Neurosci. 2009, 12:784-791.
55. Pham T.T., Giesert F., Rothig A., Floss T., Kallnik M., Weindl K., Holter S.M., Ahting U., Prokisch H., Becker L., Klopstock T., Hrabe de Angelis M., Beyer K., Gorner K., Kahle P.J., Vogt Weisenhorn D.M., Wurst W. DJ-1-deficient mice show less TH-positive neurons in the ventral tegmental area and exhibit non-motoric behavioural impairments. Genes Brain Behav. 2010, 9:305-317.
56. Ponsen M.M., Stoffers D., Booij J., van Eck-Smit B.L., Wolters E., Berendse H.W. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann. Neurol. 2004, 56:173-181.
57. Poole A.C., Thomas R.E., Yu S., Vincow E.S., Pallanck L. The mitochondrial fusion-promoting factor mitofusin is a substrate of the PINK1/parkin pathway. PLoS One 2010, 5:e10054.
58. Price D.L., Kitt C.A., Struble R.G., Whitehouse P.J., Cork L.C., Walker L.C. Neurobiological studies of transmitter systems in aging and in Alzheimer-type dementia. Ann. N.Y. Acad. Sci. 1985, 457:35-51.
59. Rakovic A., Grunewald A., Seibler P., Ramirez A., Kock N., Orolicki S., Lohmann K., Klein C. Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. Hum. Mol. Gen. 2010, 19:3124-3137.
60. Reep R.L., Winans S.S. Afferent connections of dorsal and ventral agranular insular cortex in the hamster Mesocricetus auratus. Neuroscience 1982, 7:1265-1288.
61. Rogaeva E., Johnson J., Lang A.E., Gulick C., Gwinn-Hardy K., Kawarai T., Sato C., Morgan A., Werner J., Nussbaum R., Petit A., Okun M.S., McInerney A., Mandel R., Groen J.L., Fernandez H.H., Postuma R., Foote K.D., Salehi-Rad S., Liang Y., Reimsnider S., Tandon A., Hardy J., St George-Hyslop P., Singleton A.B. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch. Neurol. 2004, 61:1898-1904.
62. Rossignol R., Gilkerson R., Aggeler R., Yamagata K., Remington S.J., Capaldi R.A. Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res. 2004, 64:985-993.
63. Sandebring A., Thomas K.J., Beilina A., van der Brug M., Cleland M.M., Ahmad R., Miller D.W., Zambrano I., Cowburn R.F., Behbahani H., Cedazo-Minguez A., Cookson M.R. Mitochondrial alterations in PINK1 deficient cells are influenced by calcineurin-dependent dephosphorylation of dynamin-related protein 1. PLoS One 2009, 4:e5701.
64. Sawyer T.F., Hengehold A.K., Perez W.A. Chemosensory and hormonal mediation of social memory in male rats. Behav. Neurosci. 1984, 98:908-913.
65. Schapira A.H., Gegg M. Mitochondrial contribution to Parkinson's disease pathogenesis. Park. Dis. 2011, 2011:159160.
66. Schwenk F., Baron U., Rajewsky K. A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res. 1995, 23:5080-5081.
67. Sedelis M., Schwarting R.K., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 2001, 125:109-125.
68. Shulman L.M. Understanding disability in Parkinson's disease. Mov. Disord. 2010, 25(Suppl 1):S131-S135.
69. Silvestri L., Caputo V., Bellacchio E., Atorino L., Dallapiccola B., Valente E.M., Casari G. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum. Mol. Gen. 2005, 14:3477-3492.
70. Taymans J.M., Van den Haute C., Baekelandt V. Distribution of PINK1 and LRRK2 in rat and mouse brain. J. Neurochem. 2006, 98:951-961.
71. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., Albanese A., Nussbaum R., Gonzalez-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B., Auburger G., Wood N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304:1158-1160.
72. Vives-Bauza C., Zhou C., Huang Y., Cui M., de Vries R.L., Kim J., May J., Tocilescu M.A., Liu W., Ko H.S., Magrane J., Moore D.J., Dawson V.L., Grailhe R., Dawson T.M., Li C., Tieu K., Przedborski S. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:378-383.
73. Vlamings R., Visser-Vandewalle V., Koopmans G., Joosten E.A., Kozan R., Kaplan S., Steinbusch H.W., Temel Y. High frequency stimulation of the subthalamic nucleus improves speed of locomotion but impairs forelimb movement in Parkinsonian rats. Neuroscience 2007, 148:815-823.
74. von Coelln R., Dawson V.L., Dawson T.M. Parkin-associated Parkinson's disease. Cell Tissue Res. 2004, 318:175-184.
75. Westermann B., Wattendorf E., Schwerdtfeger U., Husner A., Fuhr P., Gratzl O., Hummel T., Bilecen D., Welge-Lussen A. Functional imaging of the cerebral olfactory system in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2008, 79:19-24.
76. Winklhofer K.F., Haass C. Mitochondrial dysfunction in Parkinson's disease. Biochim. Biophys. Acta 2010, 1802:29-44.
77. Yamaguchi H., Shen J. Absence of dopaminergic neuronal degeneration and oxidative damage in aged DJ-1-deficient mice. Mol. Neurodegener. 2007, 2:10.
78. Yang Y., Ouyang Y., Yang L., Beal M.F., McQuibban A., Vogel H., Lu B. Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:7070-7075.
79. Yu W., Sun Y., Guo S., Lu B. The PINK1/Parkin pathway regulates mitochondrial dynamics and function in mammalian hippocampal and dopaminergic neurons. Hum. Mol. Genet. 2011, 20:3227-3240.
80. Zhou H., Falkenburger B.H., Schulz J.B., Tieu K., Xu Z., Xia X.G. Silencing of the Pink1 gene expression by conditional RNAi does not induce dopaminergic neuron death in mice. Int. J. Biol. Sci. 2007, 3:242-250.